Form 4: Fulgent Genetics CEO Ming Hsieh Reports Stock Transactions
SEC Form 4 Filing
CEO Ming Hsieh reports acquisition and disposal of Fulgent Genetics stock due to vesting of restricted stock units and tax obligations.
Summary
- Ming Hsieh, CEO of Fulgent Genetics, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
- On February 26, 2024, Hsieh acquired 13,090 shares and 20,679 shares of common stock due to the vesting of performance-based restricted stock units.
- Also on February 26, 2024, 6,997 shares and 11,053 shares were withheld to satisfy tax obligations related to the vesting of these restricted stock units at a price of $24.26.
- Hsieh also acquired 65,952 restricted stock units that vest over three years.
- Following these transactions, Hsieh directly owns 648,421 shares and indirectly owns 220,816 shares through the Dynasty Trust, 7,895,115 shares through The Ming Hsieh Trust, and 2,000 shares through Uniform Transfer to Minor Accounts.
- The report was filed on February 28, 2024, by Paul Kim as Attorney-in-Fact.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing reflects routine stock transactions related to executive compensation. The vesting of performance-based restricted stock units is a positive sign, but the tax withholding is a neutral event.
Positives
- The vesting of performance-based restricted stock units suggests the achievement of certain performance milestones.
Negatives
- The withholding of shares to cover tax obligations reduces the number of shares directly held by the CEO.
Future Outlook
The restricted stock units acquired on February 26, 2024, vest over a three-year period, suggesting continued service and potential future vesting events.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. Investors monitor these filings to gain insights into management's confidence in the company's prospects.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect routine executive compensation.
Key Dates
| Date | Description |
|---|---|
| 02/26/2024 | Date of stock transactions (acquisition and disposal). |
| 02/28/2022 | Date of grant for performance-based restricted stock units that vested on 02/26/2024. |
| 02/23/2023 | Date of grant for performance-based restricted stock units that vested on 02/26/2024. |
| 02/26/2024 | Date of grant for restricted stock units that vest over three years. |
| 02/28/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.